



**CStone Pharmaceuticals**

**基石藥業**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2616)**

## **Arrangement of Dissemination of Corporate Communications**

Pursuant to Rule 2.07A<sup>(1)</sup> of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the articles of association of CStone Pharmaceuticals (the “**Company**”), the Company will disseminate the future corporate communications of the Company (the “**Corporate Communications**”<sup>(2)</sup>) to its shareholders (the “**Shareholders**”)<sup>(3)</sup> electronically and only send corporate communications in printed form to the Shareholders upon request.

In this connection, the following arrangements came into effect from December 31, 2023.

### **ARRANGEMENTS**

#### **1. Actionable Corporate Communications<sup>(4)</sup>**

The Company will send the Actionable Corporate Communications to the Shareholders individually in electronic form by email. If the Company does not possess the email address of a Shareholder or the email address provided is not functional<sup>(5)</sup>, the Company will send the Actionable Corporate Communication in printed form together with a request form for soliciting the Shareholder’s functional email address to facilitate electronic dissemination of Actionable Corporate Communications in the future.

#### **2. Corporate Communications**

The Company will make the Corporate Communications available on its website ([www.cstonepharma.com/](http://www.cstonepharma.com/)) and the Stock Exchange’s website ([www.hkexnews.hk/](http://www.hkexnews.hk/)) and the Shareholders can read all Corporate Communications via the Website Version<sup>(6)</sup>.

### **PROVISION OF SHAREHOLDER’S EMAIL ADDRESS TO THE COMPANY**

In support of electronic communication by email, the Company recommends registered Shareholders whose shares are held in certificate form to provide the Company with their email address at any time in future by reasonable notice in writing to the Company at 22/F, New Bund Times Square, No. 399 West Haiyang Road, Pudong New District, Shanghai, the People’s Republic of China or by email to [ir@cstonepharma.com](mailto:ir@cstonepharma.com).

If non-registered Shareholders whose shares (whether or not held through a broker or custodian) are kept in the Central Clearing and Settlement System (CCASS) wish to receive Actionable Corporate Communications pursuant to the Listing Rules, they should liaise with their bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which shares are held (collectively, the “**Intermediaries**”) and provide their email address to the Intermediaries.

It is the responsibility of the Shareholders to provide email address that is functional. If the Company does not possess the email address of a Shareholder or the email address provided is not functional, the Company will act according to the above arrangements. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications to the email address provided by a Shareholder without receiving any “non-delivery message”.

## REQUEST FOR PRINTED COPY OF CORPORATE COMMUNICATIONS AND ACTIONABLE CORPORATE COMMUNICATIONS

For those Shareholders who wish to receive a printed version of all future Corporate Communications and Actionable Corporate Communications or, if for any reason, have difficulty in gaining access to the Company's website, the Company will, upon receipt of request in writing by the Shareholder to the Company at 22/F, New Bund Times Square, No. 399 West Haiyang Road, Pudong New District, Shanghai, the People's Republic of China or by email to [ir@cstonepharma.com](mailto:ir@cstonepharma.com), send future Corporate Communications and Actionable Corporate Communications to such Shareholders in printed form free of charge.

Please note that the preference in receiving Corporate Communications in printed form of a Shareholder will be valid unless being revoked or superseded or until expired on the last day of the following financial year of the Company after receipt of instruction (whichever is earlier). Further request in writing will be required if a Shareholder prefers to continue receiving printed copy of future Corporate Communications and Actionable Corporate Communications.

### Notes:

- 1 *With effect from December 31, 2023.*
- 2 *Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report and its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) the quarterly report, if any; (d) a notice of meeting; (e) a listing document; (f) a circular; and (g) a proxy form.*
- 3 *Holder(s) of the Share(s) of the Company.*
- 4 *Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders of the Company on how they wish to exercise their rights or make elections as the Company's securities holders.*
- 5 *It is the responsibility of a Shareholder to provide email address that is functional. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications to the email address provided by a Shareholder without receiving any "non-delivery message".*
- 6 *The version of Corporate Communications being published, in both English and Chinese, on the Company's website.*

To: CStone Pharmaceuticals (the “Company”)  
 22/F, New Bund Times Square  
 No. 399 West Haiyang Road, Pudong New District  
 Shanghai, the People’s Republic of China

**Provision of Email Address and/or Request for Printed Copy of Corporate Communications<sup>1</sup> and Actionable Corporate Communications<sup>2</sup>**

Information of Shareholders:

Name(s) (in English)	:	
Name(s) (in Chinese)	:	
Email address	:	
Email address (re-type)	:	
Contact telephone number	:	

Please mark (X) in ONLY ONE of the following boxes (**ONLY** applicable for dissemination arrangement via printed copy):

	To receive the <b>printed version</b> of all future Corporate Communications and Actionable Corporate Communications; <b>OR</b>
	To <b>cancel</b> prior request(s), if any, of printed version(s) of all future Corporate Communications and Actionable Corporate Communications. Shareholders will refer to the online versions to be published on the Company’s website and the website of The Stock Exchange of Hong Kong Limited for all future Corporate Communications or the electronic form of Actionable Corporate Communications to be received by email <sup>4</sup> (as the case may be).

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Address: \_\_\_\_\_

(Please use **ENGLISH BLOCK LETTERS**)

Name of contact person: \_\_\_\_\_

Contact telephone number: \_\_\_\_\_

Notes:

1. Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors’ report and its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) the quarterly report, if any; (d) a notice of meeting; (e) a listing document; (f) a circular; and (g) a proxy form.
2. Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders of the Company on how they wish to exercise their rights or make elections as the Company’s security holders.
3. It is the Shareholder’s responsibility to provide email address that is functional. If the Company does not receive the completed form or the email address provided is not functional, the Company will send the Actionable Corporate Communications in printed form together with a request for soliciting your functional email address to facilitate electronic dissemination of Actionable Corporate Communications in the future. The Company will be considered to have complied with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited if it sends Actionable Corporate Communications to the email address provided by a Shareholder without receiving any “non-delivery message”.
4. Please complete all your details clearly. If no box, or more than one box, is marked, the Company reserves the right to treat this request as void.
5. In the case of joint registered holders of any shares, all of the joint shareholders should jointly sign this request in order to be valid.
6. If more than one email addresses are provided, the Company will only adopt the first email address as set out above.
7. This request will be valid unless being revoked or superseded or until expired on the last day of the following financial year of the Company after receipt of instruction (whichever is earlier). Further request in writing will be required if Shareholder prefers to continue receiving printed copy of future Corporate Communications and Actionable Corporate Communications.
8. For avoidance of doubt, the Company does not accept any other instructions given on this request. Any other instructions inserted on this request will be void.

**PERSONAL INFORMATION COLLECTION STATEMENT**

- (i) “Personal Data” in this statement has the same meaning as “personal data” in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong (“**PDPO**”).
- (ii) Your Personal Data provided in this request will be used in connection with, including but not limited to, the Company’s electronic dissemination of Corporate Communications and to liaise with you on other matters relating to your holdings in the Company. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this request.
- (iii) Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, share registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.
- (iv) You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the privacy officer of the Company at 22/F, New Bund Times Square, No. 399 West Haiyang Road, Pudong New District, Shanghai, the People’s Republic of China or by email at [ir@cstonepharma.com](mailto:ir@cstonepharma.com).